6,621 Shares in Veracyte, Inc. (NASDAQ:VCYT) Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft bought a new position in shares of Veracyte, Inc. (NASDAQ:VCYT) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 6,621 shares of the biotechnology company’s stock, valued at approximately $262,000.

A number of other institutional investors have also recently bought and sold shares of the stock. KBC Group NV lifted its position in Veracyte by 13.7% in the 3rd quarter. KBC Group NV now owns 2,677 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 323 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Veracyte by 21.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,778 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 496 shares during the last quarter. Virtus Fund Advisers LLC raised its holdings in Veracyte by 32.9% during the third quarter. Virtus Fund Advisers LLC now owns 4,798 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 1,189 shares in the last quarter. Blue Trust Inc. lifted its holdings in Veracyte by 100.6% during the 3rd quarter. Blue Trust Inc. now owns 2,781 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 1,395 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Veracyte by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 42,766 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 2,135 shares during the period.

Insiders Place Their Bets

In other Veracyte news, insider John Leite sold 1,050 shares of Veracyte stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $43.25, for a total transaction of $45,412.50. Following the transaction, the insider now directly owns 73,810 shares of the company’s stock, valued at approximately $3,192,282.50. The trade was a 1.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karin Eastham sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $40.30, for a total value of $403,000.00. Following the completion of the sale, the director now owns 18,497 shares in the company, valued at $745,429.10. This trade represents a 35.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,038 shares of company stock valued at $1,008,297 in the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

VCYT has been the topic of several research analyst reports. UBS Group increased their price objective on shares of Veracyte from $43.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Scotiabank increased their price target on shares of Veracyte from $40.00 to $44.00 and gave the company a “sector outperform” rating in a report on Friday, November 8th. StockNews.com cut Veracyte from a “buy” rating to a “hold” rating in a report on Tuesday. Leerink Partners upped their target price on Veracyte from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Morgan Stanley upped their price objective on Veracyte from $26.00 to $28.00 and gave the company an “underweight” rating in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Veracyte has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Veracyte Price Performance

Shares of NASDAQ:VCYT opened at $46.14 on Friday. Veracyte, Inc. has a 1 year low of $18.61 and a 1 year high of $47.32. The company’s 50 day simple moving average is $42.13 and its 200 day simple moving average is $35.21.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.16. The firm had revenue of $115.86 million during the quarter, compared to analysts’ expectations of $109.81 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The business’s revenue for the quarter was up 28.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.03) earnings per share. Equities analysts anticipate that Veracyte, Inc. will post 0.38 EPS for the current year.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.